Arvinas (ARVN) Liabilities and Shareholders Equity (2017 - 2026)

Arvinas' (ARVN) quarterly Liabilities and Shareholders Equity came in at $647.5 million in Q1 2026, down 35.32% year-on-year from $1.0 billion in Q1 2025, and down 9.81% quarter-over-quarter from $717.9 million in Q4 2025.

Arvinas (ARVN) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends

Arvinas' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $647.5 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 35.32% year-over-year to $647.5 million in Q1 2026; TTM through Mar 2026 was $3.1 billion, a 31.29% decrease from a year earlier, with the FY2025 full-year figure at $717.9 million, down 34.22% from the prior year.
  • Liabilities and Shareholders Equity eased to $647.5 million in Q1 2026 per ARVN's latest filing, from $717.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.5 billion in Q1 2022 and bottomed at $647.5 million in Q1 2026.
  • The 5-year median for Liabilities and Shareholders Equity is $1.2 billion (2024), against an average of $1.1 billion.
  • Across the five-year window, Liabilities and Shareholders Equity soared 118.47% in 2022 and sank 35.32% in 2026, its largest moves.
  • Year by year, Liabilities and Shareholders Equity stood at $1.3 billion in 2022, then gained by 2.82% to $1.3 billion in 2023, then dropped by 16.34% to $1.1 billion in 2024, then sank by 34.22% to $717.9 million in 2025, then decreased by 9.81% to $647.5 million in 2026.
  • Per Business Quant, the three latest ARVN Liabilities and Shareholders Equity figures stand at $647.5 million (Q1 2026), $717.9 million (Q4 2025), and $844.3 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 311.58 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 78.88 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 8.55 Bn
4 NuCana 279.75 Bn 279.75 Bn - 39.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - 811.27 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 10.03 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 2.25 Bn
10 Arvinas 519.68 Mn -95.22 Mn - 647.50 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 647.50 Mn
Dec 31, 2025 717.90 Mn
Sep 30, 2025 844.30 Mn
Jun 30, 2025 909.30 Mn
Mar 31, 2025 1.00 Bn
Dec 31, 2024 1.09 Bn
Sep 30, 2024 1.17 Bn
Jun 30, 2024 1.28 Bn
Mar 31, 2024 1.21 Bn
Dec 31, 2023 1.30 Bn
Sep 30, 2023 1.06 Bn
Jun 30, 2023 1.08 Bn
Mar 31, 2023 1.18 Bn
Dec 31, 2022 1.27 Bn
Sep 30, 2022 1.33 Bn
Jun 30, 2022 1.41 Bn
Mar 31, 2022 1.49 Bn
Dec 31, 2021 1.58 Bn
Sep 30, 2021 1.60 Bn
Jun 30, 2021 644.03 Mn